GSK bets USD 1.3b on HutchMed's KRAS-EGFR conjugate

GSK has agreed to pay USD 110 million upfront for exclusive rights to develop and commercialize HMPL-A830, a pre-clinical antibody-targeted therapy conjugate (ATTC) designed to simultaneously inhibit KRAS and EGFR, in a deal that could total USD 1.295 billion for HutchMed (China) Limited (Nasdaq: HCM).

The agreement grants GSK worldwide rights excluding Mainland China, Hong Kong, Macau, and Taiwan. HutchMed retains full development and commercialization rights in those territories and will conduct the global Phase I program, which is expected to initiate in H2 2026 (NCT07718581). GSK assumes responsibility for all subsequent development and commercialization outside greater China. The deal also gives GSK a right of first negotiation on one earlier-stage ATTC candidate. Financial terms include up to USD 1.185 billion in development, regulatory, and commercial milestones, plus tiered royalties on net sales.

HMPL-A830 is described by HutchMed as a KRAS small-molecule inhibitor payload conjugated to an anti-EGFR antibody, designed to simultaneously inhibit KRAS and EGFR. The company says the format delivers the KRAS inhibitor directly to EGFR-expressing tumor cells while simultaneously blocking both EGFR and KRAS signaling, which the company argues may improve efficacy and tolerability compared with systemic KRAS inhibition. HutchMed distinguishes its ATTCs from conventional antibody-drug conjugates by using targeted-therapy payloads rather than cytotoxic chemotherapeutic agents.

The agreement gives GSK access to the platform before HMPL-A830 has generated human data, although HutchMed already has two related ATTC candidates in clinical development. HMPL-A251, a HER2-directed conjugate, entered Phase I/IIa testing in December 2025, while HMPL-A580, which couples an EGFR antibody to a PI3K/PIKK inhibitor payload, dosed its first patient in March 2026. Those studies could provide early evidence on the broader feasibility of HutchMed's conjugate design, although their payloads and targets differ from HMPL-A830.

GSK has moved aggressively to build an external ADC and conjugate portfolio, with several recent deals including licensing B7-H3- and B7-H4-directed ADCs from Hansoh Pharma and a preclinical prostate cancer ADC from Syndivia. HutchMed's strategy differs from conventional systemic KRAS inhibitors by attempting to concentrate the payload in EGFR-expressing tumors while blocking both pathways. The development of KRAS-EGFR conjugates remains in the very early stages. Jacobio Pharma's JAB-BX600 — an EGFR-directed ADC delivering a KRAS G12D inhibitor payload — was reported to be targeting an investigational new drug submission in H2 2026, placing it at approximately the same development stage.

---

Spot something wrong? Report an issue with this article